SAN DIEGO & REHOVOT, Israel–(BUSINESS WIRE)–Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced that it will present data from ongoing research using a blood-based methylation assay for cancer detection during the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program held May 29-31, 2020. The six-marker assay serves as an initial component of Nucleix’s screening tests generating significant signal in early cancers and leveraging existing, low-cost PCR technology.
Go to the inbox of the email
address you just used to sign up.
Find the email sent by us. It has the subject line
“Nucleix: Please Confirm Subscription” and I
sent from “email@example.com”.
Click on the link inside the
email and you’re good to go.